Pfizer Prostate Cancer Drug Combo Reduced Progression Risk by 55%
Pfizer's combination of TALZENNA and XTANDI significantly reduced the risk of disease progression or death by 55% compared to placebo plus XTANDI in men with HRR gene-mutated metastatic castration-resistant prostate cancer.
New York, USA – Pfizer Inc. (NYSE: PFE) announced new positive results from a cohort of the Phase 3 TALAPRO-2 study evaluating the combination of TALZENNA (talazoparib) and XTANDI (enzalutamide) in men with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene mutations.
The study demonstrated that the TALZENNA plus XTANDI combination reduced the risk of radiographic progression or death (rPFS) by 55% compared to placebo plus XTANDI. The median rPFS has not yet been reached in the combination arm, while it was 13.8 months in the placebo arm. The findings were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
An exploratory analysis of patients with BRCA1/2 mutations showed an 80% reduction in the risk of progression or death. Patients with other HRR gene mutations also showed benefit from the combination compared to placebo.
The safety profiles of TALZENNA and XTANDI were generally consistent with their known profiles. Pfizer has submitted an application for the combination therapy to the U.S. Food and Drug Administration (FDA) and expects a decision in 2023. A similar application has also been submitted to the European Medicines Agency (EMA).